{"id":533534,"date":"2021-03-10T14:10:01","date_gmt":"2021-03-10T14:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=533534"},"modified":"2021-03-10T14:10:01","modified_gmt":"2021-03-10T14:10:01","slug":"cytomegalovirus-cmv-infection-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cytomegalovirus-cmv-infection-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_533534.html","title":{"rendered":"Cytomegalovirus (CMV) Infection Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cytomegalovirus (CMV) Infection Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Cytomegalovirus (CMV) Infection Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Cytomegalovirus (CMV) Infection Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Cytomegalovirus (CMV) Infection, historical and forecasted epidemiology as well as the Cytomegalovirus (CMV) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\">As per the National Organization of Rare Disorders, <strong>Cytomegalovirus infection (CMV)<\/strong> is a viral infection that rarely causes obvious illness. The virus that causes CMV is part of the herpes virus family and, like other herpes viruses may become dormant for a period of time and then be reactivated. The virus can pass from an infected, pregnant mother to her child through the shared blood supply (umbilical cord). When a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. Cytomegalovirus retinitis may occur in some people with impaired immune systems due to AIDS, cytotoxic chemotherapy, or long-term immunosuppression.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get FREE sample copy at:&nbsp;<\/strong><br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cytomegalovirus-cmv-infection-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/cytomegalovirus-cmv-infection-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">The <strong>Cytomegalovirus (CMV) Infection market report<\/strong> also covers emerging drugs, current treatment practices, Cytomegalovirus (CMV) Infection market share of the individual therapies, current and forecasted Cytomegalovirus (CMV) Infection Market Size from 2017 to 2030 segmented by seven major markets.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report provides a detailed current <strong>Cytomegalovirus (CMV) Infection treatment practice<\/strong><strong>\/algorithm<\/strong>, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Cytomegalovirus (CMV) Infection Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/a14280d313b7b190ab3f20d3d0b02958.jpg\" alt=\"Cytomegalovirus (CMV) Infection Market\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cytomegalovirus (CMV) Infection Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">In 2017, the total <strong>Sero-Prevalence of Cytomegalovirus Infection (CMV)<\/strong> was found to be around 368,516,410 in the 7MM.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The estimates suggest that the total number of <strong>diagnosed Cytomegalovirus (CMV) Infection patients<\/strong> in the 7MM were found to be 110,580 in 2017.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Among the European countries, France had the highest <strong>diagnosed Cases of Cytomegalovirus (CMV) Infection<\/strong> with approximately 8,946 cases, followed by the United Kingdom which had a diagnosed population of approximately 7,445 in 2017. On the other hand, Italy had the lowest diagnosed population of around 3,892 in 2017.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the United States, the total number of HSCT (allogeneic HSCT) patients were found out to be 9,474 in 2017. It has been observed that approximately 46.90% of total HSCT (Allogeneic) patients are diagnosed with Cytomegalovirus (CMV) Infection.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The total number of Cytomegalovirus (CMV) Retinitis cases among HIV patients in the United States was observed to be approximately 5,948 in 2017.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Key Benefits of Cytomegalovirus (CMV) Infection Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cytomegalovirus (CMV) Infection market report provides an in-depth analysis of <strong>Cytomegalovirus (CMV) Infection Market Size, Share, Trend<\/strong>, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Cytomegalovirus (CMV) Infection market report will help in developing business strategies by understanding the <strong>Cytomegalovirus (CMV) Infection Market trends &amp; developments<\/strong>, key players, and future market competition that will shape and drive the Cytomegalovirus (CMV) Infection market in the upcoming years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Cytomegalovirus (CMV) Infection market report covers <strong>Cytomegalovirus (CMV) Infection current treatment practices<\/strong>, emerging drugs, market share of the individual therapies in 7 MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides a detailed assessment of the C<strong>ytomegalovirus (CMV) Infection market<\/strong> in terms of market drivers &amp; barriers, Unmet Needs, market opportunities, patient population,&nbsp; comparative analysis of pipeline products with detailed clinical profiles, and other factors.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cytomegalovirus-cmv-infection-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Cytomegalovirus (CMV) Infection Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>Cytomegalovirus (CMV) Infection therapeutic market<\/strong> is categorized into two groups i.e. prophylactic and therapeutics. The expected launch of potential therapies may increase market size in the coming years, assisted by an increase in the diagnosed population of Cytomegalovirus Infection.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Cytomegalovirus (CMV) Infection market outlook<\/strong> section of the report helps to build a detailed comprehension of the historic, current and forecasted Cytomegalovirus (CMV) Infection market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cytomegalovirus-cmv-infection-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Cytomegalovirus (CMV) Infection market trend<\/strong><\/a> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cytomegalovirus (CMV) Infection Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Cytomegalovirus (CMV) Infection epidemiology<\/strong> section covers insights about the historical and current Cytomegalovirus (CMV) Infection patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cytomegalovirus (CMV) Infection Drugs Uptake and Key Market Players<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Cytomegalovirus (CMV) Infection Drugs<\/strong> Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cytomegalovirus (CMV) Infection market or expected to get launched in the market during the study period. The analysis covers Cytomegalovirus (CMV) Infection market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\">The<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cytomegalovirus-cmv-infection-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong> Cytomegalovirus Infection market size<\/strong><\/a> is anticipated to change during the forecasted period owing to the expected launch of emerging therapies. There are many pipeline therapies under development for the prevention of Congenital Cytomegalovirus and treatment of Cytomegalovirus infection following transplant (allogeneic hematopoietic stem cell transplantation\/Solid-organ transplantation).<\/p>\n<p style=\"text-align: justify;\"><strong>Cytomegalovirus (CMV) Infection companies:<\/strong><br \/>Shire<br \/>Roche<br \/>ViraCyte<br \/>Helocyte<br \/>Clinigen Group<br \/>CSL Behring<br \/>GlaxoSmithKline<br \/>Gilead Sciences<br \/>Biotest Pharma Gmbh<br \/>Merck Sharp &amp; Dohme Corp<br \/><strong>And many others<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cytomegalovirus (CMV) Infection therapies covered in the report include:<\/strong><br \/>Maribavir<br \/>Viralym-M <br \/>Valtrex<br \/>V160 <br \/>Triplex<br \/>Valcyte<br \/>Foscavir<br \/>Prevymis<br \/>CytoGam<br \/>Cytotect CP<br \/>Vistide<br \/><strong>And many more<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Cytomegalovirus (CMV) Infection Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Cytomegalovirus (CMV) Infection Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Cytomegalovirus (CMV) Infection Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Cytomegalovirus (CMV) Infection Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Cytomegalovirus (CMV) Infection Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Cytomegalovirus (CMV) Infection Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Cytomegalovirus (CMV) Infection Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Cytomegalovirus (CMV) Infection Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Cytomegalovirus (CMV) Infection Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Cytomegalovirus (CMV) Infection Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Cytomegalovirus (CMV) Infection Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Cytomegalovirus (CMV) Infection Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Cytomegalovirus (CMV) Infection Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Cytomegalovirus (CMV) Infection Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Cytomegalovirus (CMV) Infection Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Cytomegalovirus (CMV) Infection Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">Cytomegalovirus (CMV) Infection Pipeline<br \/><\/a><\/strong>Cytomegalovirus (CMV) Infection Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cytomegalovirus (CMV) Infection market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cytomegalovirus-cmv-infection-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd. 2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cytomegalovirus-cmv-infection-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Cytomegalovirus (CMV) Infection Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Cytomegalovirus (CMV) Infection, historical and forecasted epidemiology as well as the Cytomegalovirus (CMV) Infection market trends in the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cytomegalovirus-cmv-infection-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_533534.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-533534","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/533534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=533534"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/533534\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=533534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=533534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=533534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}